DDR gene mutations associated with complete response to chemo in bladder cancer

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.

July 18, 2025

Vol.51 No.28

Drugs & Targets

FDA gives TAR-200 Priority Review for invasive bladder cancer

FDA has granted Priority Review to TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine have shed new light on the location and function of power-generating waves on cancer cell membranes. The scientists say the waves, generated by rhythmic propagation of enzymes that produce energy from glucose, could potentially be used to better stage cancers and as targets for new cancer drugs.

July 11, 2025

Vol.51 No.27

In Brief

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Nicholas M. Jaidar was named senior administrator for oncology at the Department of Oncology at the Johns Hopkins University School of Medicine and the Johns Hopkins Hospital.

June 27, 2025

Vol.51 No.25

DDR gene mutations associated with complete response to chemo in bladder cancer

YOU MAY BE INTERESTED IN

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

FDA gives TAR-200 Priority Review for invasive bladder cancer

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Renew today!

Subscriber content

Never miss an issue!

Login